HUS2300040I1 - Pirrolo[2,3-d]pirimidinil-, pirrolo[2,3-b]pirazinil- és pirrolo[2,3-d]-piridinil- akrilamidok - Google Patents

Pirrolo[2,3-d]pirimidinil-, pirrolo[2,3-b]pirazinil- és pirrolo[2,3-d]-piridinil- akrilamidok

Info

Publication number
HUS2300040I1
HUS2300040I1 HUS2300040C HUS2300040C HUS2300040I1 HU S2300040 I1 HUS2300040 I1 HU S2300040I1 HU S2300040 C HUS2300040 C HU S2300040C HU S2300040 C HUS2300040 C HU S2300040C HU S2300040 I1 HUS2300040 I1 HU S2300040I1
Authority
HU
Hungary
Prior art keywords
pyrrolo
pyrazinyl
pyrimidinyl
acrylamides
pyridinyl
Prior art date
Application number
HUS2300040C
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52144776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS2300040(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of HUS2300040I1 publication Critical patent/HUS2300040I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
HUS2300040C 2013-12-05 2023-11-14 Pirrolo[2,3-d]pirimidinil-, pirrolo[2,3-b]pirazinil- és pirrolo[2,3-d]-piridinil- akrilamidok HUS2300040I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912074P 2013-12-05 2013-12-05
EP14816404.9A EP3077395B1 (en) 2013-12-05 2014-11-20 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

Publications (1)

Publication Number Publication Date
HUS2300040I1 true HUS2300040I1 (hu) 2023-12-28

Family

ID=52144776

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE17200940A HUE054560T2 (hu) 2013-12-05 2014-11-20 Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil és pirrolo[2,3-d]piridinil akrilamidok
HUE14816404A HUE035264T2 (hu) 2013-12-05 2014-11-20 Pirrolo[2,3-d]pirimidinil-, pirrolo[2,3-b]pirazinil- és pirrolo[2,3-d]-piridinil- akrilamidok
HUS2300040C HUS2300040I1 (hu) 2013-12-05 2023-11-14 Pirrolo[2,3-d]pirimidinil-, pirrolo[2,3-b]pirazinil- és pirrolo[2,3-d]-piridinil- akrilamidok

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HUE17200940A HUE054560T2 (hu) 2013-12-05 2014-11-20 Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil és pirrolo[2,3-d]piridinil akrilamidok
HUE14816404A HUE035264T2 (hu) 2013-12-05 2014-11-20 Pirrolo[2,3-d]pirimidinil-, pirrolo[2,3-b]pirazinil- és pirrolo[2,3-d]-piridinil- akrilamidok

Country Status (46)

Country Link
US (3) US9617258B2 (hu)
EP (2) EP3318565B1 (hu)
JP (2) JP6192839B2 (hu)
KR (1) KR101930603B1 (hu)
CN (2) CN106061973B (hu)
AP (1) AP2016009269A0 (hu)
AR (1) AR099363A1 (hu)
AU (1) AU2014358792C1 (hu)
BR (1) BR112016012262B1 (hu)
CA (1) CA2932425C (hu)
CL (1) CL2016001216A1 (hu)
CR (1) CR20160250A (hu)
CU (1) CU24396B1 (hu)
CY (2) CY1119778T1 (hu)
DK (2) DK3077395T3 (hu)
DO (1) DOP2016000124A (hu)
EA (1) EA030472B1 (hu)
ES (2) ES2871524T3 (hu)
FI (1) FIC20230035I1 (hu)
GE (1) GEP20186840B (hu)
GT (1) GT201600098A (hu)
HR (2) HRP20171846T1 (hu)
HU (3) HUE054560T2 (hu)
IL (1) IL246038B (hu)
LT (2) LT3318565T (hu)
MA (1) MA39092B1 (hu)
MD (1) MD4649C1 (hu)
ME (1) ME02883B (hu)
MX (1) MX368464B (hu)
MY (1) MY187446A (hu)
NI (1) NI201600075A (hu)
NL (1) NL301245I2 (hu)
NO (2) NO3134430T3 (hu)
NZ (1) NZ720092A (hu)
PE (1) PE20161246A1 (hu)
PH (1) PH12016500938B1 (hu)
PL (2) PL3077395T3 (hu)
PT (2) PT3077395T (hu)
RS (2) RS61897B9 (hu)
SI (2) SI3077395T1 (hu)
SV (1) SV2016005209A (hu)
TN (1) TN2016000227A1 (hu)
TW (1) TWI548636B (hu)
UA (1) UA117040C2 (hu)
UY (1) UY35861A (hu)
WO (1) WO2015083028A1 (hu)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840517B2 (en) 2013-09-18 2017-12-12 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
ME02883B (me) * 2013-12-05 2018-04-20 Pfizer PIROLO[2,3-d]PIRIMIDINIL-, PIROLO[2,3-b]PIRAZINIL- I PIROLO[2,3-d] PIRIDINILAKRILAMIDI
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN107108601B (zh) 2014-08-28 2021-08-20 阿森纽荣股份公司 糖苷酶抑制剂
CN105712998B (zh) * 2014-12-05 2019-12-13 上海润诺生物科技有限公司 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
AU2016209046A1 (en) * 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
CN105837574B (zh) * 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
EP3288943B1 (en) * 2015-05-01 2022-09-28 Pfizer Inc. Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase
JP6564473B2 (ja) * 2015-05-29 2019-08-21 无▲錫▼福祈制▲薬▼有限公司Ｗｕｘｉ Ｆｏｒｔｕｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ Ｊａｎｕｓキナーゼ阻害剤
CN106432246B (zh) * 2015-08-05 2020-07-07 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
BR112018008966B1 (pt) 2015-11-03 2023-05-02 Theravance Biopharma R&D Ip, Llc Compostos inibidores de jak quinase, hidrato cristalino, composição farmacêutica, processos, método de preparação do hidrato cristalino e uso dos referidos compostos e hidrato cristalino no tratamento de doença respiratória
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
EP3419976B1 (en) 2016-02-25 2021-04-07 Asceneuron SA Acid addition salts of piperazine derivatives
AU2017222958B2 (en) 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
MA43680A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
EP3478687B1 (en) * 2016-06-30 2024-03-20 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
RU2019108280A (ru) 2016-08-24 2020-09-25 Аркьюл, Инк. Аминопирролопиримидиноновые соединения и способы их применения
UA123709C2 (uk) 2016-11-23 2021-05-19 Усі Форчун Фармасьютікал Ко., Лтд КРИСТАЛІЧНІ ТА СОЛЬОВІ ФОРМИ 7Н-ПІРОЛО[2,3-d]ПІРИМІДИНІВ І СПОСІБ ЇХ ОДЕРЖАННЯ
WO2018095320A1 (zh) * 2016-11-23 2018-05-31 江苏恒瑞医药股份有限公司 吡咯并六元杂芳环类衍生物的制备方法及中间体
US10851116B2 (en) 2017-01-20 2020-12-01 Leo Pharma A/S Bicyclic amines as novel JAK kinase inhibitors
EP3585790A1 (en) 2017-02-27 2020-01-01 Janssen Pharmaceutica NV [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
TWI779016B (zh) 2017-03-09 2022-10-01 美商施萬生物製藥研發 Ip有限責任公司 稠合咪唑-哌啶jak抑制劑
CN108794480A (zh) * 2017-04-28 2018-11-13 天津药物研究院有限公司 吡咯并嘧啶类化合物、其制备方法和用途
EP3619208B1 (en) 2017-05-01 2023-06-07 Theravance Biopharma R&D IP, LLC Crystalline forms of a jak inhibitor compound
CN110573157B (zh) 2017-05-01 2023-04-04 施万生物制药研发Ip有限责任公司 使用jak抑制剂化合物的治疗方法
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SG11202000602YA (en) 2017-08-01 2020-02-27 Theravance Biopharma R&D Ip Llc Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
EP3710431A4 (en) 2017-11-03 2021-07-07 Aclaris Therapeutics, Inc. SUBSTITUTED PYRROLOPYRIMIDINE JAK INHIBITORS AND METHODS FOR THEIR MANUFACTURE AND USE
JP2021502361A (ja) * 2017-11-07 2021-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 共有エピトープ−カルレティキュリン相互作用の小分子阻害薬及び使用方法
CN107857778B (zh) * 2017-11-21 2020-03-24 江苏乐斯化学有限公司 含膦酰基的α-氨基腈的制备方法
LT3733673T (lt) * 2017-12-28 2022-08-10 Daewoong Pharmaceutical Co., Ltd. Oksi-fluorpiperidino darinys, kaip kinazės inhibitorius
KR102577242B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
EP3768272A4 (en) * 2018-03-21 2021-08-11 Xibin Liao JAK INHIBITORS
CN108358797A (zh) * 2018-04-20 2018-08-03 南京农业大学 一种烷基甘氨酸的合成方法
CN108640923A (zh) * 2018-07-09 2018-10-12 湖南天地恒制药有限公司 一种托法替布关键中间体的制备方法
US20210299117A1 (en) * 2018-08-06 2021-09-30 Moexa Pharmaceuticals Limited SMAD3 Inhibitors
JP2021534244A (ja) 2018-08-10 2021-12-09 アクラリス セラピューティクス，インコーポレイテッド ピロロピリミジンｉｔｋ阻害剤
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
SG11202101785UA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc Process for preparing jak inhibitors and intermediates thereof
MA53229A (fr) 2018-09-04 2022-05-11 Theravance Biopharma R&D Ip Llc Amides de diméthyl amino azétidine utilisés en tant qu'inhibiteurs de jak
AR116114A1 (es) 2018-09-04 2021-03-31 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
JP6944496B2 (ja) * 2018-10-22 2021-10-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
CA3125039A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
JP7248256B2 (ja) * 2019-03-14 2023-03-29 上海華匯拓医薬科技有限公司 Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
CN113993585A (zh) * 2019-03-27 2022-01-28 英矽智能科技知识产权有限公司 双环jak抑制剂及其用途
KR20220004726A (ko) * 2019-05-02 2022-01-11 어클라리스 쎄라퓨틱스, 인코포레이티드 Jak 억제제로서의 치환된 피롤로피리딘
WO2020232470A1 (en) 2019-05-13 2020-11-19 Boragen, Inc. Chemical compounds
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
CN110183455B (zh) * 2019-06-18 2021-04-20 中国医科大学 氮杂双环[3.2.1]辛-3-酮类化合物及其制备方法与其用途
CN112430235B (zh) * 2019-08-26 2024-04-05 东莞市东阳光仿制药研发有限公司 一种pf-06651600中间体的制备方法
KR102228668B1 (ko) 2019-10-08 2021-03-17 (주)부흥산업사 메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법
WO2021094953A1 (en) 2019-11-14 2021-05-20 Pfizer Inc. 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
CN112824381B (zh) * 2019-11-21 2024-04-26 广东东阳光药业股份有限公司 一种哌啶胺的制备方法
CN113121413B (zh) * 2019-12-31 2024-04-09 江苏艾立康医药科技有限公司 一种jak3酶抑制剂关键中间体的制备方法
CN113121539A (zh) * 2019-12-31 2021-07-16 江苏艾立康医药科技有限公司 一种pf06651600的制备方法
BR112022010101A2 (pt) * 2019-12-31 2022-09-06 Pfizer R&D Uk Ltd Formulações em comprimido e cápsula de liberação imediata estáveis de 1-((2s,5r)-5-((7h-pirrol[2,3-d]pirimidin-4-il)amino)-2-metilpiperidin-1-il)prop-2-en-1-ona
CN111138361B (zh) * 2020-01-03 2022-05-06 中国医科大学 取代苯氧基-2-氮杂双环[3.2.1]辛烷类化合物及其制备方法和应用
CN115244055A (zh) * 2020-01-21 2022-10-25 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
US20230149407A1 (en) 2020-04-04 2023-05-18 Pfizer Inc. Methods of Treating Coronavirus Disease 2019
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
CN114835715B (zh) * 2020-06-15 2024-04-05 江苏艾立康医药科技有限公司 Pf-06651600马来酸盐及其制备方法
CN111620880B (zh) * 2020-06-15 2022-06-10 江苏艾立康医药科技有限公司 Pf-06651600 dl-酒石酸盐，晶型及其制备方法
WO2022002210A1 (zh) * 2020-07-02 2022-01-06 南京明德新药研发有限公司 嘧啶并吡咯基类氘代化合物
WO2022012587A1 (zh) * 2020-07-14 2022-01-20 苏州晶云药物科技股份有限公司 丙烯酮类化合物的丙二酸盐晶型及其制备方法
CN111995623A (zh) * 2020-08-18 2020-11-27 上海毕得医药科技有限公司 一种7-溴-4-氯-1-甲基-1H-咪唑并[4,5-c]吡啶的合成方法
KR102473645B1 (ko) 2020-08-28 2022-12-05 (주)부흥산업사 (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법
CN113061137B (zh) * 2021-04-02 2022-08-02 广西医科大学 含氮杂环衍生物或其药学上可接受的盐和用途
CN113429427A (zh) * 2021-07-05 2021-09-24 湖南南新制药股份有限公司 杂环化合物及其制备方法和药物用途
CA3228746A1 (en) * 2021-08-25 2023-03-02 Qiaojun HE Aromatic heterocyclic compound, pharmaceutical composition containing the same, and use thereof
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
WO2023151069A1 (zh) * 2022-02-14 2023-08-17 湖南南新制药股份有限公司 吡咯并[2,3-d]六元杂芳环衍生物、其制备方法和药物用途
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
CN116120347A (zh) * 2023-01-18 2023-05-16 杭州禹泓医药科技有限公司 芳杂环类化合物的晶型、其组合物、制备方法及其应用
CN116496280B (zh) * 2023-06-25 2023-09-08 北京科翔中升医药科技有限公司 氘代丙烯酰胺类jak3抑制剂药物及用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
PT1235830E (pt) 1999-12-10 2004-04-30 Pfizer Prod Inc Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
PL359563A1 (en) * 2000-06-26 2004-08-23 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
CN1726192A (zh) 2002-11-21 2006-01-25 辉瑞产品公司 3－氨基－哌啶衍生物及其制备方法
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
NZ565363A (en) 2005-07-29 2010-03-26 Pfizer Prod Inc Pyrrolo[2,3-D]pyrimidine derivatives; their intermediates and synthesis
WO2007062459A1 (en) 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Selective kinase inhibitors based on pyridine scaffold
BRPI0619817B8 (pt) 2005-12-13 2021-05-25 Incyte Corp composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição
PL2526771T3 (pl) 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
CA2731368C (en) 2008-08-06 2013-05-14 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
US20100185419A1 (en) 2008-09-05 2010-07-22 Avila Therapeutics, Inc. Algorithm for designing irreversible inhibitors
ES2464458T3 (es) 2008-12-05 2014-06-02 F. Hoffmann-La Roche Ag Pirrolopirazinil-ureas como inhibidores de quinasas
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
EP2448473A4 (en) 2009-06-30 2014-06-25 Edwards Lifesciences Corp SYSTEMS AND METHODS FOR MONITORING AND DISPLAYING A PATIENT STATUS
CN102574857B (zh) * 2009-07-08 2015-06-10 利奥制药有限公司 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物
EP3461824B1 (en) 2009-09-04 2021-08-25 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
JP5967827B2 (ja) * 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
KR20130083386A (ko) 2010-05-20 2013-07-22 에프. 호프만-라 로슈 아게 피롤로[2,3-ｂ]피라진-7-카복스아마이드 유도체 및 ＪＡＫ 및 ＳＹＫ 억제제로서의 그의 용도
RU2013105450A (ru) 2010-07-09 2014-08-20 Лео Фарма А/С Новые производные гомопиперзина в качестве ингибиторов протеинтирозинкиназ и их фармацевтическое применение
WO2012054364A2 (en) * 2010-10-22 2012-04-26 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
KR102032934B1 (ko) * 2011-12-21 2019-10-16 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피롤 6원 헤테로아릴 고리 유도체, 그의 제조 방법, 및 그의 의약 용도
EP2892534B8 (en) * 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2920171B1 (en) 2012-11-16 2018-08-29 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
SG11201503977PA (en) 2012-11-20 2015-06-29 Principia Biopharma Inc Azaindole derivatives as jak3 inhibitors
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
ME02883B (me) * 2013-12-05 2018-04-20 Pfizer PIROLO[2,3-d]PIRIMIDINIL-, PIROLO[2,3-b]PIRAZINIL- I PIROLO[2,3-d] PIRIDINILAKRILAMIDI
EP3145512B1 (en) * 2014-05-19 2019-07-17 Jiangsu Hengrui Medicine Co., Ltd. Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
GEP20186840B (en) 2018-04-10
EP3318565B1 (en) 2021-04-14
FIC20230035I1 (fi) 2023-11-22
IL246038B (en) 2020-10-29
BR112016012262A2 (pt) 2020-06-30
CU20160077A7 (es) 2017-01-10
ES2871524T3 (es) 2021-10-29
EP3077395B1 (en) 2017-11-15
US11111242B2 (en) 2021-09-07
PH12016500938A1 (en) 2016-06-27
PH12016500938B1 (en) 2016-06-27
AP2016009269A0 (en) 2016-06-30
AU2014358792C1 (en) 2021-08-26
HRP20210770T1 (hr) 2021-06-25
SV2016005209A (es) 2018-04-11
HUE054560T2 (hu) 2021-09-28
CY1124793T1 (el) 2022-11-25
CY1119778T1 (el) 2018-06-27
KR20160092012A (ko) 2016-08-03
NI201600075A (es) 2016-08-09
LT3077395T (lt) 2018-02-12
MD20160058A2 (ro) 2016-11-30
JP2016539137A (ja) 2016-12-15
JP2018008996A (ja) 2018-01-18
TWI548636B (zh) 2016-09-11
JP6192839B2 (ja) 2017-09-06
MA39092B1 (fr) 2018-09-28
CN106061973B (zh) 2019-07-09
DOP2016000124A (es) 2016-10-31
CN107417684A (zh) 2017-12-01
RS61897B9 (sr) 2021-09-30
EP3318565A1 (en) 2018-05-09
MD4649C1 (ro) 2020-04-30
SI3077395T1 (en) 2018-03-30
DK3318565T3 (da) 2021-05-25
CU24396B1 (es) 2019-04-04
NO2024001I1 (no) 2024-01-09
MD4649B1 (ro) 2019-09-30
DK3077395T3 (en) 2018-01-02
EP3077395A1 (en) 2016-10-12
US20170247372A1 (en) 2017-08-31
NL301245I2 (nl) 2023-11-20
PT3077395T (pt) 2018-01-03
GT201600098A (es) 2019-10-17
US20150158864A1 (en) 2015-06-11
BR112016012262B1 (pt) 2021-04-13
IL246038A0 (en) 2016-08-02
HRP20171846T1 (hr) 2018-01-12
PE20161246A1 (es) 2016-11-25
PL3077395T3 (pl) 2018-04-30
RS56728B1 (sr) 2018-03-30
MX368464B (es) 2019-10-02
MA39092A1 (fr) 2018-06-29
AU2014358792B2 (en) 2017-06-08
AU2014358792A1 (en) 2016-06-02
CN106061973A (zh) 2016-10-26
CA2932425A1 (en) 2015-06-11
UA117040C2 (uk) 2018-06-11
CR20160250A (es) 2016-09-19
EA201600373A1 (ru) 2016-10-31
ME02883B (me) 2018-04-20
WO2015083028A1 (en) 2015-06-11
RS61897B1 (sr) 2021-06-30
TW201524977A (zh) 2015-07-01
US20230009153A1 (en) 2023-01-12
TN2016000227A1 (fr) 2017-10-06
NO3134430T3 (hu) 2018-08-18
PT3318565T (pt) 2021-05-28
CL2016001216A1 (es) 2017-01-20
NZ720092A (en) 2019-05-31
ES2654051T3 (es) 2018-02-12
MY187446A (en) 2021-09-22
PL3318565T3 (pl) 2021-10-04
US9617258B2 (en) 2017-04-11
CA2932425E (en) 2015-06-11
CA2932425C (en) 2018-07-17
MX2016007156A (es) 2016-07-21
LT3318565T (lt) 2021-06-25
EA030472B1 (ru) 2018-08-31
AR099363A1 (es) 2016-07-20
UY35861A (es) 2015-07-31
KR101930603B1 (ko) 2018-12-18
HUE035264T2 (hu) 2018-05-02
SI3318565T1 (sl) 2021-07-30

Similar Documents

Publication Publication Date Title
HUS2300040I1 (hu) Pirrolo[2,3-d]pirimidinil-, pirrolo[2,3-b]pirazinil- és pirrolo[2,3-d]-piridinil- akrilamidok
ZA201503828B (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
IL246311A0 (en) Pyrazolo[5,1-a]pyridine derivatives and methods of using them
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
IL243525A0 (en) Benzyl-1h-pyrazolo[4,3-b]pyridines and their use
HK1225723A1 (zh) 取代的咪唑並[1，2-a]吡啶甲酰胺及其用途
EP2970278A4 (en) Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9-
ZA201507151B (en) Antiviral indolo[2,3-b]quinoxaline
PT2989105T (pt) Compostos de pirazino[1,2-a]indole, sua preparação e utilização em medicamentos
SG11201508653QA (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
TH1601003263A (th) ไพร์โรโล[2,3-d]ไพริมิดินิล, ไพร์โรโล[2,3-b]ไพราซินิล และ ไพร์โรโล[2,3-d] ไพริดินิล เอคริลเอไมด์